GALECTIN THERAPEUTICS INC. Payments to Acquire Additional Interest in Subsidiaries
GALECTIN THERAPEUTICS INC. (GALT) reported Payments to Acquire Additional Interest in Subsidiaries of $22.00 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries · last filed 2021-08-16
- GALECTIN THERAPEUTICS INC. payments to acquire additional interest in subsidiaries for the quarter ending 2021-06-30 was $22.00M.
| Period end | Payments to Acquire Additional Interest in Subsidiaries 3 month |
|---|---|
| 2021-06-30 | $22.00M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |